Printer Friendly

PALATIN'S PT-141 INCREASES SEXUAL BEHAVIOR IN FEMALE ANIMALS.

Palatin Technologies, Inc. (AMEX: PTN), Princeton, N.J., is developing PT-141 as an investigational treatment for male and female sexual dysfunction. The studies were performed by Palatin scientists in collaboration with Concordia University in Montreal.

The studies' objectives were to evaluate PT-141's ability to enhance sexual behavior in female rodents. The studies were designed to allow for the evaluation of PT-141's effect on a variety of normal precopulatory sexual behaviors that are used by female rodents to heighten sexual arousal in their male partners. Female animals given PT-141 showed a significant, dose-responsive increase in a variety of these precopulatory sexual behaviors and actively solicited sexual contact from the males. Importantly, PT-141 treatment increased the female rodents' desire to copulate.

"These data suggest that stimulation of melanocortin receptors in the brain by PT-141 selectively increased motivation for sexual activity in female rodents. The results indicate that PT-141 has potential to offer a unique treatment for women with desire disorders," said Dr. Annette Shadiack, Ph.D, director, Biological Research at Palatin.

Perry Molinoff, M.D., executive vice president of Research & Development of Palatin said, "We are very excited about these results, which, in combination with the positive safety results from our Phase 1 clinical study in men, provide the basis for advancing this investigational drug into Phase 2 efficacy trials in women with Female Sexual Dysfunction (FSD) early next year."

Palatin recently completed a Phase 1 safety trial with PT-141 in men that demonstrated a positive safety profile. PT-141 was well tolerated at all doses, there were no significant changes in blood pressure, heart rate or respiration rate, and investigators reported no serious side effects. A Phase 2A efficacy study of patients with erectile dysfunction is scheduled to begin later this year.

PT-141 is a peptide analog of the neuropeptide hormone (alpha)-MSH ((alpha)-melanocyte-stimulating hormone). Scientists have determined that receptors for this class of molecules (melanocortin receptors) play a role in several behaviors including appetite and sexual arousal. Recent findings indicate the effects on sexual function may be stimulated through melanocortin receptors in the brain. As a result, Palatin believes PT-141 has the potential to offer a unique treatment for both male and female sexual dysfunction.

Palatin Technologies, Inc. is a development-stage biopharmaceutical company. The company is currently conducting clinical investigations with its lead drug, PT-141, for the treatment of erectile dysfunction, and is developing additional therapeutic compounds discovered using its enabling peptide platform technology, MIDAS. Additionally, Palatin is developing a product for infection imaging, LeuTech(R), based on a proprietary radiolabeled monoclonal antibody.

For more information, visit http://www.palatin.com or call 609/520-1911.
COPYRIGHT 2001 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Business
Date:Dec 1, 2001
Words:435
Previous Article:NAPRO GETS NEW PACLITAXEL FORMULATION PATENT.
Next Article:AGENCOURT COMPLETES DNA SEQUENCING PROJECT FOR WHITEHEAD.
Topics:


Related Articles
Leaping lizards and male impersonators: are there hidden messages? By imitating male mating behavior, all-female lizard species apparently enhance...
Animals' fancies: why members of some species prefer their own sex.
Maternal care may leave brain legacy. (Behavior).
PALATIN REPORTS POSITIVE PT-141 PHASE 1 CLINICAL RESULTS.
PALATIN'S MALE ERECTILE DYSFUNCTION TREATMENT EFFICACIOUS.
King and Palatin form strategic alliance to jointly develop and commercialize PT-141 as an innovative treatment for sexual dysfunction.
Palatin Technologies expands patent portfolio in the treatment of sexual dysfunction.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters